Hyperpolarized Carbon 13-Based MRI for the Detection of Radiation-Induced Cardiotoxicity in Patients Receiving Thoracic Radiation

Inclusion Criteria

• Benign or malignant tumor of the breast (left-sided only) or thorax
• Stage I to IV. If stage IV, patient must have life expectancy equal to or greater than 6 months
• Eastern Cooperative Oncology Group (ECOG) performance status 0-1
• The patient must be deemed an appropriate candidate for standard of care radiation therapy
• Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 90 days following completion of participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately * A female of child-bearing potential is any woman (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria: ** Has not undergone a hysterectomy or bilateral oophorectomy; or ** Has not been naturally postmenopausal for at least 12 consecutive months (i.e., has had menses at any time in the preceding 12 consecutive months). * A female of postmenopausal status is defined as patients over 60 or greater OR patients age 50-59 who meet the following criteria: ** status post (s/p) bilateral oophorectomy, OR ** With intact uterus without menses in the past 12 months OR, ** With biochemical confirmation of post-menopausal status (estradiol in the menopausal range based on local laboratory criteria)
• Ability to understand and the willingness to sign a written informed consent

Exclusion Criteria

• Prior radiation involving the heart
• Subjects may not be receiving any known cardiotoxic agents for the 6 months prior to the study and during the study
• Diagnosis of connective tissue disorders, including systemic lupus erythematosus, scleroderma, or dermatomyositis
• Patients with stage IV cancer with life expectancy of less than 6 months
• Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that, in the opinion of the investigator, would limit compliance with study requirements
• Estimated glomerular filtration rate (eGFR) < 30
• Any contraindication to MRI (including, but not limited to metal implants and devices contraindicated at 3T, non-magnetic resonance [MR] compatible breast tissue expanders and IV ports, claustrophobia)
• History of psychiatric or addictive disorders that would preclude obtaining informed consent
• Subjects must not be pregnant or nursing due to the potential for congenital abnormalities and the potential of this regimen to harm nursing infants